Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients

BACKGROUND: The efficacy of antitumour necrosis factor alpha (anti-TNF-α) treatment is well recognised in rheumatoid arthritis (RA) but remains controversial in systemic lupus erythematosus (SLE). Therefore, the role of anti-TNF-α treatment in ‘Rhupus’, a disease sharing features of RA and SLE, is s...

Descripción completa

Detalles Bibliográficos
Autores principales: Danion, François, Sparsa, Laetitia, Arnaud, Laurent, Alsaleh, Ghada, Lefebvre, François, Gies, Vincent, Martin, Thierry, Lukas, Cédric, Durckel, Jean, Ardizzone, Marc, Javier, Rose-Marie, Kleinmann, Jean-François, Moreau, Paul, Blaison, Gilles, Goetz, Joelle, Chatelus, Emmanuel, Gottenberg, Jacques-Eric, Sibilia, Jean, Sordet, Christelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Connective Tissue Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761296/
https://www.ncbi.nlm.nih.gov/pubmed/29435362
http://dx.doi.org/10.1136/rmdopen-2017-000555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761296/
https://www.ncbi.nlm.nih.gov/pubmed/29435362
http://dx.doi.org/10.1136/rmdopen-2017-000555

Ejemplares similares